Latest

Latest hepatocellular carcinoma News

  • Latest hepatocellular carcinoma news stories and updates. What is happening today? All recent hepatocellular carcinoma news and developments. Live coverage and timeline of hepatocellular carcinoma. All you need to know about hepatocellular carcinoma.
Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver…
Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer…
Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable…
Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
Uncovering a key signaling pathway linking liver cancer and fibrosis
Cheaper Cancer And Chronic Conditions Medicines Now On PBS
New funding for cancer, kidney disease and baby health research
Breaking new ground: Novel human stem cell-derived liver organoids
NO ONE SHOULD GO THROUGH THIS ALONE – SUPPORTING AUSTRALIANS WITH ONE OF OUR MOSTLY DEADLY CANCERS
Cancer Council ACT announces the 2025 Cancer Research Grant Recipients at Government House
New trial examines common household pill to reduce liver cancer risk
A drug dismantles a metabolic barrier to anti-tumor immunity
Grants Target Medical Research And Innovation
Life-saving technology detects patients in early, curable stages of liver cancer
Melbourne To Host Global Health Summit
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy
Immunotherapy for liver cancer can be improved with new insights into immune cells
CAR T cells armed with IL-15 show promise in treating solid cancers
Mater Surgeon Removes Huge 2kg Tumour From Man’s Liver
Biomarker may predict immunotherapy response in liver cancer
Revealing the role of immune cells in liver cancer
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Seven Early-Career Scientists will Attend the AACR Annual Meeting with Ludwig Support
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer…
Five Ludwig Cancer Research scientists named Fellows of the American Association for Cancer Research
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
New treatment offers hope for advanced liver cancer
New discovery for treatment of primary liver cancer
Aspartame hazard and risk assessment results released
Imfinzi plus Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four…
Manchester researchers awarded £1 million to test potential life-saving technology for early detection of liver cancer
Cancer Council welcomes the first Roadmap to Liver Cancer Control and Clinical Guidelines
5 things to know about liver cancer
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
New tests seek to predict liver cancer relapse and improve survival rates
Baylor receives more than $5.8 million in CPRIT funding
Dramatic rise in liver cancer in Australia’s tropical and equatorial north
Positive CHMP Opinion Etranacogene Dezaparvovec
CSL’s Novel Gene Therapy HEMGENIX Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living
U.S. Food and Drug Administration approves CSL’s HEMGENIX , first gene therapy for hemophilia B
Imjudo in combination with Imfinzi approved in US for patients with unresectable liver cancer
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
New molecular subset of pediatric liver cancer identified
Tremelimumab accepted under Priority Review in US for patients with unresectable liver cancer

© 2026 - The National Tribune Australia